Trump Administration Rejects Medicare Coverage for Obesity Medications Ignoring Public Health Needs

President Donald Trump’s administration has made a controversial decision by refusing to cover obesity medications under Medicare. The Centers for Medicare and Medicaid Services (CMS) announced this late Friday, indicating that drugs like Wegovy and Zepbound will not be included in Medicare’s Part D prescription drug coverage. This action primarily impacts elderly Americans, who rely heavily on Medicare for their health care needs.
This decision represents a stark departure from the proposal put forth by Trump’s predecessor, Joe Biden. After Biden won re-election, he aimed to finalize a rule extending coverage for these high-demand treatments. However, with Trump returning to office in January, the new administration swiftly dismissed the proposal. Notably, Dr. Mehmet Oz, a controversial figure with no prior experience in public health leadership, was confirmed to head CMS just days before the announcement.
Despite a significant portion of the American public supporting coverage for obesity treatments, Trump’s Health and Human Services secretary, Robert F. Kennedy Jr., who has been vocal against such medications, continues to shape health policy in a direction that neglects public health concerns. The absence of a detailed explanation from CMS regarding their decision raises questions about the motivations behind it.
Advocates for the coverage argue that addressing obesity efficiently can lead to substantial long-term savings by reducing costly health complications such as heart attacks and strokes. In fact, statistics from insurance consultant Mercer show that 44% of U.S. companies with 500 or more employees provided coverage for obesity drugs in the past year. Yet, this administration’s refusal to cover these drugs stands at odds with efforts to promote long-term health and wellness.
While Medicare does cover these medications under certain conditions—for patients with heart disease, for example—this broader refusal to cover obesity drugs limits access for many who could benefit from them. The rejection of such a significant health initiative aligns with a pattern of prioritizing corporate interests over public wellbeing, further confirming the Trump administration’s troubling approach to healthcare in America.